1 ) Wu F‚ Zhao S‚ Yu B‚ et al: A new coronavirus associated with human respiratory disease in China. Nature‚ 579: 265-269‚ 2020.
2 ) Meinhardt J‚ Radke J‚ Dittmayer C‚ et al: Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci‚ 24: 168-175‚ 2021.
3 ) Lamers MM‚ Beumer J‚ van der Vaart J‚ et al: SARSCoV-2 productively infects human gut enterocytes. Science‚ 369: 50-54‚ 2020.
4 ) Miyakawa K‚ Jeremiah SS‚ Ohtake N‚ et al: Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles. J Mol Cell Biol‚ 12: 987-990‚ 2020.
5 ) Jeremiah SS‚ Miyakawa K‚ Ryo A: Detecting SARSCoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology. J Mol Cell Biol‚ 14 (4): mjac023‚ 2022.
6 ) Miyakawa K‚ Jeremiah SS‚ Kato H‚ et al: Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera. J Mol Cell Biol‚ 13: 918-920‚ 2022.
7 ) Miyakawa K‚ Jeremiah SS‚ Yamaoka Y‚ et al: Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2. Front Med (Lausanne),9: 811004‚ 2022.
8 ) VanBlargan LA‚ Errico JM‚ Halfmann PJ‚ et al: An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med‚ 28: 490-495‚ 2022.
9 ) Miyakawa K‚ Kubo S‚ Stanleyraj Jeremiah S‚ et al: Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection. Open Forum Infect Dis‚ 9: ofab626‚ 2022.
10) Bentley EG‚ Kirby A‚ Sharma P‚ et al: SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID- 19. bioRxiv . 2021. doi : 10.1101/2021.12.26.474085
11) Menni C‚ Valdes AM‚ Polidori L‚ et al: Symptom prevalence‚ duration‚ and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet‚ 399: 1618-1624‚ 2022.
12) Miyakawa K‚ Machida M‚ Kawasaki T‚ Nishi M‚ Akutsu H‚ Ryo A: Reduced Replication Efficacy of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in “Mini-gut” Organoids. Gastroenterology‚ 163: 514-516‚ 2022.
13) Miyakawa K‚ Kato H‚ Ohtake N‚ Jeremiah SS‚ Ryo A: Enhancement of humoral and cellular immunity against SARS-CoV-2 by a third dose of BNT162b2 vaccine in Japanese healthcare workers. J Infect Dis‚ jiac344‚ 2022.